Baidu
map

Blood:CD137缺陷是一种新型先天性免疫缺陷,与早发型淋巴瘤相关

2019-09-10 MedSci MedSci原创

中心点:CD137缺陷是一种新发的先天免疫缺陷,伴有免疫失调和EB病毒相关的淋巴发育不良。本研究强调了CD137在免疫平衡中的关键作用,与免疫缺陷和癌症免疫治疗相关。摘要:免疫反应失调是导致癌症、自身免疫和免疫缺陷等多种疾病的本质原因。本研究对4位来自无亲缘关系的家庭的患者进行研究,这4位患者表现为免疫缺陷、自身免疫病和恶性肿瘤。研究人员在编码肿瘤坏死因子超家族成员CD137/4-1BB的TNFR

中心点:

CD137缺陷是一种新发的先天免疫缺陷,伴有免疫失调和EB病毒相关的淋巴发育不良。

本研究强调了CD137在免疫平衡中的关键作用,与免疫缺陷和癌症免疫治疗相关。

摘要:

免疫反应失调是导致癌症、自身免疫和免疫缺陷等多种疾病的本质原因。本研究对4位来自无亲缘关系的家庭的患者进行研究,这4位患者表现为免疫缺陷、自身免疫病和恶性肿瘤。

研究人员在编码肿瘤坏死因子超家族成员CD137/4-1BB的TNFRSF9基因上筛选出4个不同的纯合突变,导致蛋白表达缺失或减少。对免疫监测至关重要的淋巴细胞反应,包括活化、增殖和分化,均受到了影响。

CD137基因重组可逆转上述缺陷。CD137缺乏症是一种新的先天免疫缺陷,其特征是淋巴细胞缺陷合并早发型EB病毒相关性淋巴瘤

总而言之,本研究阐明了CD137在人类免疫稳态和抗肿瘤反应中的功能作用和相关性。

原始出处:

Ido Somekh, et al.CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis.Blood 2019 :blood.2019000644; doi: https://doi.org/10.1182/blood.2019000644

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1664081, encodeId=098d16640816d, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Fri Jan 31 20:14:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720633, encodeId=48461e2063376, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4266, encryptionId=392442664d, topicName=CD137)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=644432894735, createdName=cqlidoudou, createdTime=Sun Mar 29 04:14:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928013, encodeId=bf1f192801366, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4263, encryptionId=a6b54263ae, topicName=CD13)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Wed Oct 02 19:14:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369466, encodeId=d98d1369466ed, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488993, encodeId=07bf1488993d1, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1664081, encodeId=098d16640816d, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Fri Jan 31 20:14:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720633, encodeId=48461e2063376, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4266, encryptionId=392442664d, topicName=CD137)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=644432894735, createdName=cqlidoudou, createdTime=Sun Mar 29 04:14:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928013, encodeId=bf1f192801366, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4263, encryptionId=a6b54263ae, topicName=CD13)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Wed Oct 02 19:14:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369466, encodeId=d98d1369466ed, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488993, encodeId=07bf1488993d1, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
    2020-03-29 cqlidoudou
  3. [GetPortalCommentsPageByObjectIdResponse(id=1664081, encodeId=098d16640816d, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Fri Jan 31 20:14:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720633, encodeId=48461e2063376, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4266, encryptionId=392442664d, topicName=CD137)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=644432894735, createdName=cqlidoudou, createdTime=Sun Mar 29 04:14:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928013, encodeId=bf1f192801366, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4263, encryptionId=a6b54263ae, topicName=CD13)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Wed Oct 02 19:14:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369466, encodeId=d98d1369466ed, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488993, encodeId=07bf1488993d1, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
    2019-10-02 hyf028
  4. [GetPortalCommentsPageByObjectIdResponse(id=1664081, encodeId=098d16640816d, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Fri Jan 31 20:14:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720633, encodeId=48461e2063376, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4266, encryptionId=392442664d, topicName=CD137)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=644432894735, createdName=cqlidoudou, createdTime=Sun Mar 29 04:14:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928013, encodeId=bf1f192801366, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4263, encryptionId=a6b54263ae, topicName=CD13)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Wed Oct 02 19:14:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369466, encodeId=d98d1369466ed, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488993, encodeId=07bf1488993d1, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
    2019-09-12 huirong
  5. [GetPortalCommentsPageByObjectIdResponse(id=1664081, encodeId=098d16640816d, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Fri Jan 31 20:14:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720633, encodeId=48461e2063376, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4266, encryptionId=392442664d, topicName=CD137)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=644432894735, createdName=cqlidoudou, createdTime=Sun Mar 29 04:14:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928013, encodeId=bf1f192801366, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4263, encryptionId=a6b54263ae, topicName=CD13)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Wed Oct 02 19:14:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369466, encodeId=d98d1369466ed, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488993, encodeId=07bf1488993d1, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Sep 12 12:14:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]

相关资讯

Blood:GATA6过表达可诱导CD137配体异常表达,进而促进皮肤T细胞淋巴瘤进展

中心点:GATA6过表达可诱导异常CD137配体(CD137L)在皮肤T细胞淋巴瘤(CTCL)的肿瘤细胞上表达。在CTCL细胞中,CD137-CD137L相互作用促进细胞增殖和迁移,或许可作为治疗靶点。摘要:CD137及其配体CD137L,分别在活化的T细胞和抗原提呈细胞上表达。近期研究表明CD137L和CD137在肿瘤细胞中异常表达,特别是某些血液恶性肿瘤,这些分子在肿瘤细胞上相互作用可促进肿瘤

Baidu
map
Baidu
map
Baidu
map